Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.31 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.31 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 3/20 | 0.38 |
| ▸ | NOX1 | Q9Y5S8 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL16496288 | 0.90 | KDM4E (0.34) | SNCANOX1MAPTGAATDP1 | |
| Bromide SCHEMBL3712204 | 0.88 | SNCA (0.38) | SNCANOX1MAPTGAATDP1 | |
| Iodide SCHEMBL16496354 | 0.87 | TDP1 (0.36) | SNCANOX1GAATDP1ALDH1A1 | |
| Bromide SCHEMBL3711404 | 0.87 | SNCA (0.37) | SNCANOX1MAPTGAATDP1 | |
| Iodide SCHEMBL3712800 | 0.86 | SNCA (0.35) | SNCANOX1MAPTGAATDP1 | |
| SCHEMBL972682 | 0.86 | SNCA (0.46) | SNCANOX1MAPTGAATDP1 | |
| Bromide SCHEMBL3714443 | 0.85 | SNCA (0.38) | SNCANOX1MAPTGAATDP1 | |
| SCHEMBL1470932 | 0.82 | SNCA (0.40) | SNCANOX1MAPTGAATDP1 | |
| SCHEMBL7044213 | 0.80 | SNCA (0.41) | SNCANOX1MAPTGAATDP1 | |
| SCHEMBL12592413 | 0.80 | SNCA (0.43) | SNCANOX1MAPTGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306576-A1 | COMPOUNDS AND METHODS RELATING THERETO | PHARMALUCIA LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| WO-2010097626-A2 | COMPOUNDS AND METHODS RELATING THERETO | PHARMALUCIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306576-A1 | COMPOUNDS AND METHODS RELATING THERETO | QSOX1, PYM1, SQOR | ACHE 1759/4885SLC6A2 981/4885SLC6A3 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.